Health

United Imaging and Carrollton Regional Medical Center Accelerate Installation of the Revolutionary uCT® ATLAS Scanner

Highlights Agility of Both Organizations in Responding to Patient Needs HOUSTON, Sept. 21, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that it delivered its flagship uCT ATLAS scanner earlier than first scheduled, at the ...

2022-09-21 21:00 1203

Charsire's New Drug Aims to Capture Multi-Billion-Dollar Dementia Treatment Market

TAINAN CITY, Taiwan, Sept. 21, 2022 /PRNewswire/ -- Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease and vascular dementia using its patented technology of Multi-Glycan Complex and soybeans as raw materials. BAC has completed Phase II ...

2022-09-21 20:00 1006

The 6th China Health and Senior Care Conference held in southwest Chinese city Shizhu

CHONGQING, China, Sept. 21, 2022 /PRNewswire/ -- On August 30th, the 6th China Health and Senior Care Conference was held in Huangshui Town, a summer resort in Shizhu Tujia Autonomous County, southwestChina's Chongqing Municipality. Hosted by the Revolutionary Committee of the Chinese Kuomintang ...

2022-09-21 17:07 1171

Mediaseek's Proprietary Neurofeedback Engine "Alpha Switch" and Its Smartphone Application Mentioned in International Journal

- Engine and App Used in Research Paper on Chronic Low Back Pain Treatment at Pain Center of Chiba University Hospital Published in "Scientific Reports" - TOKYO, Sept. 21, 2022 /PRNewswire/ -- Mediaseek, Inc. (hereinafter referred to as "Mediaseek") based inTokyo is pleased to announce that a res...

2022-09-21 14:00 1150

GMP cell CDMO I Peace, Inc. in collaboration with universities successfully converted human dermal fibroblasts into oligodendrocyte by direct reprogramming

PALO ALTO, Calif., Sept. 20, 2022 /PRNewswire/ -- Koji Tanabe of I Peace, Inc. ( https://www.ipeace.com ) and a researcher Hiroko Nobuta of theUniversity of California, San Francisco (currently assistant professor at Rutgers University) successfully achieved the direct repr...

2022-09-21 05:39 1174

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tr...

2022-09-20 19:25 1455

Waterdrop Launches the WFind System

BEIJING, Sept. 19, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, recently launched "Waterdrop Family Insurance Needs Diagnosis" ("WFind"), a system d...

2022-09-19 22:00 2789

Special interview with Dr. Patrick Yu-Wai-Man on International LHON Awareness Day

WUHAN, China and SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- September 19th is International LHON Awareness Day. LHON is a debilitating disease that leads to quick vision loss concomitantly or successively. It mostly impacts young adolescent males and brings tremendous physical and psychological st...

2022-09-19 20:00 2382

Taiwan's Anyong Biotechnology First To Employ Seafood Stem-Cell Freezing

KAOHSIUNG, Taiwan, Sept. 19, 2022 /PRNewswire/ -- Anyong Biotechnology, the world-class aquatic food processing company based inTaiwan, is now the first company in the region to employ Cells Alive System (CAS) technology fromJapan. It ranks as the most advanced freezing technology inAsia and is a...

2022-09-19 16:20 1383

New treatment for rare cancer cholangiocarcinoma approved in Australia

* Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement * PEMAZYRE® (pemigatinib) is available via a co-pay access program in Australia SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- A NEW targeted therapy to treat a rare bile duct c...

2022-09-15 21:00 1502

Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance

SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for...

2022-09-15 17:07 1393

J INTS BIO, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022)

SEOUL, South Korea, Sept. 15, 2022 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' at the 2022 edition of the European Society for Medical Oncology Congress (ESMO 2022) held inParis, France from 9th to 13th September...

2022-09-15 14:12 1120

United Imaging Announces Clinical System Installations at Huntsman Cancer Institute at the University of Utah

Agreement envisions expansion of cutting-edge clinical services. HOUSTON, Sept. 14, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that TheCenter for Quantitative Cancer Imaging

2022-09-14 21:00 1404

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment ...

2022-09-14 20:30 2476

DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY

AUCKLAND, New Zealand, Sept. 14, 2022 /PRNewswire/ -- New Zealand based soft tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor, Dr.Catherine Mohr as a Non-Executive Director to the board.

2022-09-14 13:05 1289

MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS

MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center ('MD Anderson') and Radiopharm Theranostics Limited ('Radiopharm')(ASX: RAD) today announced the launch of Radiopharm Ventu...

2022-09-14 11:09 1239

GBB Lands USD 15M Pre-Series B Funding Led by Tiger Jade Capital

HONG KONG, Sept. 13, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") is pleased to announce today the completion of itsUSD 15M Pre-series B funding led by Tiger Jade Capital (hereinafter referred to as "Tiger Jade"). The funding was oversubscribed and upsized with participat...

2022-09-14 09:08 1802

New Study by Lunit and MGH Validates Effectiveness of AI as Aid in Chest X-Ray Interpretation - Published in JAMA Network Open

* Joint study with Massachusetts General Hospital proves that Lunit's AI-powered chest x-ray analysis software enhances the overall performance and efficiency of radiologists SEOUL, South Korea, Sept. 13, 2022 /PRNewswire/ -- A recent study published in

2022-09-13 22:16 1358

EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development... to "accelerate entering the overseas market"

* An expert from Invitae and Ambry Genetics, U.S. genome analysis companies * EDGC states, "We will expand the overseas genome analysis market and advance into the global liquid biopsy technology market by recruiting a global talent in the genome field" * Worked in a non-profit research orga...

2022-09-13 21:00 1601

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (...

2022-09-13 20:00 2215
1 ... 137138139140141142143 ... 280